Search clinical trials for: Non-Hodgkin

Total 1997 results

Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Large B-cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Case Comprehensive Cancer Center
AbbVie; Genmab; Recordati Rare Diseases

Not yet recruiting

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Non-Hodgkin Lymphoma | Cytokine Release Syndrome

United States
Vittoria Biotherapeutics
University of Pennsylvania

Not yet recruiting

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) (VIPER101)

T Cell Non-Hodgkin Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Not yet recruiting

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics (COSMIC)

Melanoma | Non-Hodgkin Lymphoma | Breast Carcinoma | Lung Non-Small Cell Carcinoma | Colorectal Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns...
Janssen Research & Development, LLC

Not yet recruiting

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Myelofibrosis | Non Hodgkin Lymphoma | Chronic Myeloid Leukemia | Hematologic Malignancy | Aplastic Anemia | Myelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Bone Marrow Transplant Rejection | Acute Lymphoblastic Leukemia (ALL), Adult
Tianjin Medical University Cancer Institute and...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | B-Cell Non-Hodgkin Lymphoma-Refractory

China
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Arvinas Inc.

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

United States, Spain
Dren Bio
Novotech (Australia) Pty Limited

Recruiting

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma

Australia, Hong Kong, Korea, Republic of, Singapore, Taiwan
Mayo Clinic

Recruiting

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Indolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin Lymphoma

United States
Boston Immune Technologies and Therapeutics

Not yet recruiting

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Peripheral T-cell Lymphoma | NHL | Cutaneous T Cell Lymphoma
Murdoch Childrens Research Institute

Not yet recruiting

A Study Investigating the Change in Metabolism Phenotype in Paediatric, Adolescent & Young Adults With Hodgkin or Non-Hodgkin Lymphoma. (PEGASUS)

Hodgkin Lymphoma | Non Hodgkin Lymphoma

Australia
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
ImmunityBio, Inc.

Not yet recruiting

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma Refractory/ Relapsed
Chinese PLA General Hospital

Recruiting

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

Non-hodgkin Lymphoma

China
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
Sinocelltech Ltd.

Not yet recruiting

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, B-cell

China
Guangdong Ruishun Biotech Co., Ltd
Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital

Not yet recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

B-cell Non-Hodgkin's Lymphoma
Peking University Cancer Hospital & Institute
Nanjing Legend Biotech Co.

Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed B-cell Non-Hodgkin Lymphoma | Refractory B-cell Non-Hodgkin Lymphoma

China
Instituto Nacional de Cancer, Brazil

Recruiting

PTCy and ATG for MSD and MUD Transplants

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Hodgkin Lymphoma | Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

Brazil
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

China
Sana Biotechnology

Recruiting

Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma

United States
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Taiwan, Spain, Korea, Republic of, Thailand, Australia, Italy, Malaysia, Turkey
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China
920th Hospital of Joint Logistics Support Force...
Shanghai PerHum Therapeutics Co., Ltd.

Recruiting

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell | CAR-T

China
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Nathan Denlinger
Bristol-Myers Squibb

Recruiting

CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | Diffuse Large B-Cell Lymphoma-Recurrent | Follicular Lymphoma-Recurrent | High Grade B-Cell Lymphoma-Recurrent | Primary Mediastinal Large B-Cell Lymphoma-Recurrent | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma-Recurrent and other conditions

United States
Shanghai Simnova Biotechnology Co.,Ltd.
Wuhan Union Hospital, China

Recruiting

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

China
Shenzhen TargetRx, Inc.
Institute of Hematology & Blood Diseases Hospital, China

Recruiting

TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Non Hodgkin Lymphoma | Hematologic Malignancy | Acute Lymphoblastic Leukemia, Adult

China
Shanghai Zhongshan Hospital

Recruiting

The Pathogenesis and Prognostic Factors of Lymphoma

Lymphoma | Hodgkin Lymphoma | Non-hodgkin Lymphoma

China
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico, Australia, Israel, Korea, Republic of, Romania, Serbia, Spain, Taiwan
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute

Recruiting

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma | Non Hodgkin Lymphoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Not yet recruiting

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Anaplastic Large Cell Lymphoma, ALK-negative | CD30-Positive Diffuse Large B-Cell Lymphoma | Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type

United States
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Spain, United Kingdom
UNC Lineberger Comprehensive Cancer Center

Recruiting

Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors (AYAConnect)

Sarcoma | Obesity | Leukemia | Cancer | Breast Cancer | Breast Neoplasms | Nasopharyngeal Carcinoma | Physical Activity | Hodgkin Disease | Hodgkin Lymphoma | Brain Tumor | Ewing Sarcoma | Non Hodgkin Lymphoma | Chondrosarcoma | Mental Health | Malignant Neoplasm | Myeloma | Central Nervous System Tumor | Germ Cell Tumor | Bone Tumor | Osteoid Sarcoma and other conditions

United States
Henan Cancer Hospital

Recruiting

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

Non-hodgkin Lymphoma,B Cell

China
Fondazione Italiana Linfomi - ETS
Kite, A Gilead Company

Recruiting

SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Non-hodgkin Lymphoma,B Cell

Italy
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Italy, Korea, Republic of, Australia, France, Spain, Malaysia, Taiwan, Poland, United States, United Kingdom, Turkey, Belgium, Thailand, Czechia
AstraZeneca

Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA)

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin

Australia, Korea, Republic of, United Kingdom, Italy, Germany, France, United States, Spain

Search clinical trials for: Non-Hodgkin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations